According to the FDA, at least 72% of drugs used in the USA are manufactured abroad. As demonstrated by recent negative consequences resulting from the COVID-19 pandemic, the risks of offshoring likely surpass the benefits. Moreover, other supply chain issues, such as geopolitical conflicts, brand damage, and intellectual property theft are significant risks that weigh against manufacturing pharmaceuticals in distant countries.
Because of pandemic related issues and advances in technology, it is now likely that a reshoring innovation and supply chain strategy can be successfully implemented in North America for any pharmaceutical product. A viable US business model for pharmaceutical manufacturing depends upon the ability to utilize technological innovations and modern supply chains. A reshoring strategy can be successful in North America, not only in the short term because supporting government policies are now in place, but also in the long term, because supporting technology and supply chain sustainability will increase profitability.
Due to the efforts of C-SOPS based at Rutgers University, the Massachusetts Institute of Technology, the National Science Foundation, FDA, and leading US-based pharmaceutical companies, such as Janssen, Vertex, Pfizer, and Eli Lilly, now is the time to begin the movement of pharmaceutical manufacturing back to North America.
https://www.pharmtech.com/view/reshoring-pharmaceutical-manufacturing-to-the-us-can-we-do-it